Vivus (VVUS) Qsymia Numbers Lowered at Needham & Company
Get Alerts VVUS Hot Sheet
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Needham & Company analyst Alan Carr reiterated Hold rating and lowered estimates on Vivus (NASDAQ: VVUS) ahead of Q1 earnings and spring review.
Carr comments, "Qsymia prescriptions have remained relatively flat through 1Q14. Management indicated that the sales force reconfiguration process had a negative impact on sales in Jan and Feb. We continue to believe that patient awareness is a key factor for success in the weight loss space. The absence of a direct-to-consumer campaign at Vivus may therefore limit sales potential. We are reducing Qsymia sales estimates based on the latest prescription data."
The firm's new 1Q14 and 2014 Qsymia sales estimates are $7.5M (was $8.0M) and $55.5M (was $67.0M). Their new 2015 Qsymia sales estimate is $153.0M (was $198.0M).
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $4.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Malaysia Airports Holdings Bhd (MAHB:MK) (MYPRF) to Neutral
- Midday movers: RH, Estee Lauder rise; Tesla falls
- H.C. Wainwright Reiterates Sell Rating on Hut 8 Mining Corp. (HUT)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!